1
Early infantile epileptic encephalopathy (EIEE) with a burst suppression pattern, also known by the eponym of Ohtahara syndrome, is a rare and severe form of epileptic encephalopa thy characterized by earlyonset of intractable seizures, with mostly tonic spasms or, more rarely, partial seizures and a specific pattern on electroencephalogram known as suppres sion burst.
2 EIEE has a neonatal or early infantile onset and the natural course consists of progressive neurological dysfunction manifesting with concomitant cognitive and motor impairment leading to severe developmental delay (DD) or intellectual dis ability (ID). EIEE belongs to a broader class of disorders known as agedependent epileptic encephalopathies, with evolving clinical phenotype and electroencephalogram characteristics as the brain matures. 3 The majority of patients with EIEE subse quently develop infantile spasms (IS), or West syndrome, later in childhood. In some children, the epileptic phenotype may later evolve to Lennox-Gastaut syndrome by 6 years of age. 4 The etiology of EIEE is heterogeneous; structural abnormali ties of the brain such as Aicardi syndrome, cortical dysgenesis, novel 9q34.11 gene deletions encompassing combinations of four mendelian disease genes: STXBP1, SPTAN1, ENG, and TOR1A
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porencenphaly, and hemimegalencephaly may be accompanied by EIEE, whereas inborn errors of metabolism such as glycine encephalopathy and Leigh syndrome have been associated with other cases. 2, 4 More recently, studies have ascertained that EIEE with a burstsuppression pattern is genetically heterogeneous as well, with causative mutations identified in at least 12 genes (Supplementary Table S1 , online). 1, [5] [6] [7] [8] In addition to the 12 known genes, one individual with EIEE and a de novo balanced translocation disrupting the SRGAP2 gene has recently been reported. 9 Of note, two of the genes previously implicated in the etiol ogy of EIEE, STXBP1, and SPTAN1, are both located within the same 9q34.11 genomic region. To date, only three patients with microdeletions encompassing both STXBP1 and SPTAN1 have been described. 8, 10, 11 Two subjects presented with the character istic clinical features of EIEE. 8, 11 Although the authors of the sec ond study do not specifically mention SPTAN1, it and STXBP1 are likely deleted from the chromosome of their patient pre senting with IS. 10 De novo missense, nonsense, frameshift, and splicesite mutations, as well as genomic deletions of STXBP1 have been found in association with EIEE, suggesting STXBP1 haploinsufficiency as a cause of this epileptic phenotype. 8, [11] [12] [13] [14] However, a 4bp deletion within STXBP1 exon 4, resulting in a premature stop 41 codons downstream in the sixth of 20 exons, has been identified in one child of Japanese ancestry who pre sented with IS but did not exhibit the classical features consis tent with EIEE. 12 Furthermore, other publications reporting the clinical cases of patients of diverse ethnic backgrounds affected with epilepsy and carrying STXBP1 mutations sometimes failed to identify the burstsuppression pattern on electroencephalo gram characteristic of EIEE. 10, 15, 16 Finally, a de novo truncating STXBP1 mutation has been found in a 21yearold patient with ID and no evidence of epilepsy, expanding the clinical spectrum associated with molecular defects of STXBP1. 17 Therefore, the complete range of phenotypic features caused by STXBP1 mutations and deletions remains to be elucidated. Herein, we present clinical and highresolution molecular stud ies of 10 patients with 9q34.11 deletions in order to better delin eate the clinical manifestations associated with STXBP1 and SPTAN1 haploinsufficiencies and to characterize the clinical presentations associated with possible cisgenetic effects when additional potentially dosage sensitive genes are involved.
mAteRiALs And metHOds

Human subjects
All human subjects research was approved by the Institutional Review Board of Baylor College of Medicine (BCM). We studied 10 unrelated children (six males and four females, patient (P)1-P10) with variable clinical phenotypes, who were found to have a loss in DNA copy number in the 9q34.11 region revealed by array comparative genomic hybridization (CGH). Each subject was originally identi fied among patients referred for clinical array CGH at the BCM Medical Genetics Laboratory (P3-P6) or PerkinElmer Signature Genomic Laboratories (P1, P2, and P7-P10) for a diverse range of clinical indications. Four patients (P1, P2, P7, and P8) were identified by SignatureChipOS v1.1 105K oligo wholegenome array (Agilent Technologies, Santa Clara, CA) and two patients (P9 and P10) were identified by SignatureChipOS v2.0 135K oligo wholegenome array (Roche NimbleGen, Madison, WI). P4 was identified by BCM CMA v7.1 105 K oligo wholegenome array (Agilent Technologies). P6 was identified by BCM CMA v7.4 105K oligo exontargeted array (Agilent Technologies). P3 and P5 were identified by BCM CMA v8.1 180K oligo exon targeted array (Agilent Technologies). Informed consent for the research use of genetic material and clinical information was obtained from the parent or guardian of each patient. Peripheral blood samples were obtained from individuals and available family members. All subjects had apparently nor mal Gbanded chromosome analyses. Clinical details appear in Supplementary Materials and Methods, online.
Array-cGH studies
Patients' genomic DNA was extracted from peripheral blood samples according to the manufacturers' protocols. Two sepa rate custom, highresolution 9q34 arrays were designed using a 60K array format (Agilent Technologies, Santa Clara, CA) and were used on the basis of availability at time of patient ascertainment. Version 1 of the custom array had an average probe spacing of ~1,250 bp per probe; version 2 had an aver age spacing of ~250 bp per probe. Sexmatched DNA samples from either a normal male or female individual were used as a hybridization reference control. DNA digestion, labeling, and hybridization were performed according to the manufacturer's instructions (Agilent Technologies). Data were analyzed using Agilent Genomic Workbench Software (Agilent Technologies) and plotted using the R Statistical Computing Package (R Core Development Team). Insufficient DNA was available for direct analysis of P4 and P8; therefore, wholegenome amplification was performed on patient and control DNA according to the manufacturer's instructions (SigmaAldrich, St Louis, MO) before array hybridization.
Fluorescence in situ hybridization analysis
Chromosomes for fluorescence in situ hybridization analyses were obtained from peripheral blood lymphocytes using stan dard procedures to independently confirm the findings detected by array CGH. Fluorescence in situ hybridization studies were performed on all children and available parents using bacterial artificial chromosome or fosmid probes mapped within the 9q34.11 region.
Polymerase chain reaction breakpoint analysis
Polymerase chain reaction (PCR) primers were designed to flank each patient's deletion breakpoints on the basis of aCGH data. Longrange PCR was employed to amplify the deletionspecific junction fragment using the manufacturer's protocol (Takara Bio, Otsu, Japan). PCR products were Sanger sequenced (Lone Star, Houston, TX) and compared with the reference human genome sequence using the UCSC Genome Browser.
ResULts
We identified 10 patients with microdeletions involving the 9q34.11 region among patients referred for array CGH for a diverse set of clinical indications at two diagnostic laborato ries. All deletions were also observed with fluorescence in situ hybridization analysis using bacterial artificial chromosome or fosmid probes specific for the deleted region as an independent experimental verification. Clinical manifestations are summa rized in Table 1 . The deletions were de novo in eight of eight cases in which parents were available.
To determine the size, extent, and genomic content of the deletions, patients' samples were analyzed by customdesigned, highresolution 9q34 array CGH. The genomic intervals deleted and the corresponding nucleotide positions of the breakpoints (GRChr37/hg19, 2009) were delineated ( Figure 1 , Table 2 ). The deletions vary in size from 67 kb to 2. Table 1 ). In P1, the proximal deletion breakpoint was located within intron 15 of the STXBP1, removing the 3′ gene portion, including exons 16-20 from isoform A and exons 16-19 from isoform B ( Figure  2 ). P1 was also the only member of our cohort whose deletion involves all four discussed genes ( Figure 1) . In P10, the 9q34.11 deletion encompassed two disease genes, STXBP1 and ENG (Figure 1) . The smallest deletion, 67 kb, involved exons 1-4 of the STXBP1 gene and was found in P5 (Figure 2) . Deletions in two patients (P6 and P9) included SPTAN1 but did not involve STXBP1 (Figure 1) . In P6 the TOR1A gene was also deleted (Figure 1 ). Deletions containing TOR1A were also found in P1, P7, and P8 (Figure 1) . A total of five patients, P5 in our study, two patients reported by Deprez et al., 16 one patient reported by Milh et al., 14 and one patient reported by Saitsu et al., 11 had small deletions including annotated coding sequence of only STXBP1 (Figure 2) .
Although we did not observe any correlation between dele tion size and the severity of patients' phenotypes, correla tions between specific phenotypic features and gene content of a patient's copynumber variation were apparent ( Table 1) .
Subjects with deletions of STXBP1 coding sequence were more likely to have epilepsy. Moreover, one patient with disruption of SPTAN1 displayed defects in myelination. One individual with a deletion encompassing the TOR1A gene manifested dystonia. Finally, a patient with an ENG deletion was found to have an arteriovenous malformation. discUssiOn Deletions involving 9q34.11 result in a wide range of clinical phenotypes because of differences in the deletion size, gene content within the deleted region, and function of each individ ual affected gene. There are at least four known genes mapped to this region that are apparently dosage sensitive, STXBP1, SPTAN1, ENG, and TOR1A. Each individual gene, and poten tially selected combinations in cis, may contribute to the com plex phenotypes observed in patients with 9q34.11 deletions.
STXBP1 encodes syntaxin binding protein 1, an evolution arily conserved neuronal protein that is vital for the process of calcium ion-dependent exocytosis in neurons as well as in neuroendocrine cells. 18, 19 STXBP1, a member of the SM (Sec1/ Munc18) family, binds to syntaxin, thus promoting its stability, and regulates soluble Nethylmaleimidesensitive factor attach ment protein receptor (SNARE) complex formation with ensu ing priming and fusion of synaptic vesicles. Therefore, STXBP1 has a fundamental function in synaptic vesicle release, acting in conjunction with the vesicular SNARE protein vesicleas sociated membrane protein 2 (VAMP2, synaptobrevin 2) and the target membrane SNARE proteins syntaxin 1 and synapto somalassociated protein 25 (SNAP25) to facilitate membrane fusion and neurotransmitter release. 19, 20 Patients with EIEE4 have been found to have missense, non sense, frameshift, and splicesite mutations as well as whole gene and intragenic deletions of STXBP1. 8, 13, 14, 21 In addition, there is increasing awareness that STXBP1 mutations may also cause IS as the presenting epileptic feature, broadening the rec ognized clinical phenotypic consequences of genetic variation at the STXBP1 locus. 10, 12, 16 In one of the same studies impli cating a link between STXBP1 and IS, five of the six subjects harboring STXBP1 mutations manifested nonspecific epileptic phenotypes. 16 Similarly, in another report, two individuals with STXBP1 mutations were affected with nonsyndromic epilep sy. 15 In our cohort, only four of six subjects (P2-P5 Table 1 ) identified with STXBP1 coding sequence deletions presented with epilepsy. Each patient's constellation of findings lacked the clinical and electroencephalogram characteristics suggestive of EIEE, supporting the concept that alterations in STXBP1 cod ing sequence may be associated with diverse epileptic presen tations. Our patients' phenotypes were consistent with IS with later evolution to infantile myoclonic epilepsy (P2), tonic local ization related epilepsy (6 years, P3), nocturnal myotonic atonic epilepsy (P4), and neonatalonset generalized epilepsy with later evolution to Lennox-Gastaut syndrome (P5). Of note, one patient with a partial STXBP1 deletion (patient P5) exhibited a severe neurological phenotype as did three previously reported patients with intragenic STXBP1 deletions (Figure 2) , 14, 16 ASD, autism spectrum disorders; AVM, arteriovenous malformation; CC, corpus callosum; CT, computerized tomography; DF, dysmorphic features; EEG, electroencephalogram; EIEE, early infantile epileptic encephalopathy; IS, infantile spasms; ID, intellectual disability; MRI, magnetic resonance imaging; NA, not applicable or not available; P, patient.
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suggesting that isolated STXBP1 haploinsufficiency is associ ated with epilepsy and progressive neurodegeneration.
Response to antiepileptic therapy in our cohort varied exten sively; three patients (P3-P5) exhibited intractable epilepsy, whereas another (P2) responded to treatment at 8 months of age. In three other studies, some patients demonstrated a ben eficial response to treatment with vigabatrin alone or in combi nation with other antiepileptic compounds and continued clin ical resolution of early epileptic features. 10, 14, 16 Nevertheless, the number of patients evaluated is small and the natural history associated with STXBP1 alterations remains to be delineated. Therefore, robust conclusions regarding therapeutic approaches or their efficacy remain undefined.
Two patients in our cohort harboring STXBP1 deletions (P1 and P10; Table 1 ) had no evidence of epilepsy at age 2 or 6 years, respectively, and presented with phenotypes con sistent with severe to profound nonsyndromic ID. These two patients, together with a 21yearold subject with a de novo truncating STXBP1 mutation (Supplementary Table  S3 , online) and no epilepsy reported by Hamdan et al., 17 suggest that STXBP1 alterations may lead to a phenotype of severe to profound ID without overt epilepsy or abnormal Chromosome 9 genomic coordinates (GRChr37/hg19) 131,500,000 132,500,000 133,500,000 −1
Figure 1 custom-designed high-resolution array comparative genomic hybridization (cGH) analysis of the 9q34.11 region, including genes of interest (in scale)
. Array CGH probes with absolute value log 2 patient:control ratios greater than 0.5 within the deleted region are colored for ease of visualization. The locations of the STXBP1, ENG, SPTAN1, and TOR1A genes are indicated along the top of the graph in black. Ninety-four additional RefSeq genes are depicted as horizontal gray rectangles. All data are presented according to the GRChr37/hg19 assembly. electroencephalogram. Furthermore, the severe encephalop athy associated with STXBP1 mutations may be independent of the presence or severity of epilepsy. However, because P1 is younger than the oldest age at epilepsy presentation in our cohort (P3) and P10 is the same age, it is possible that one or both could experience more seizures as their brains mature. Symptoms consistent with autism spectrum disorders (ASDs) were found in two patients (P4 and P5, Table 1 ) with ORIGINAL RESEARCH ARTICLE STXBP1 deletions. These findings are not surprising given the high comorbidity of ID and ASDs and the recent work delineat ing mutations in synaptogenesis and synaptic function genes in association with ASDs. [22] [23] [24] Whereas a previous study did not identify STXBP1 mutations or deletions in 142 subjects with ASDs, 15 these results should be interpreted with caution, as the criteria used to diagnose ASDs in that study were not reported and the cohort was too small to evaluate for potential rare vari ants. 25 In contrast, a more recent study demonstrated autistic features in three subjects with STXBP1 mutations, 14 suggesting that ASDs may be part of the broad clinical spectrum associ ated with STXBP1 disruption.
Additional neurological features, including motor dyspraxia, ataxia, tremor, dyskinesia, and pyramidal signs, were observed in association with STXBP1 deletions (in P2, P4-P6, and P10, Table 1 ). Literature review reveals detection of several types of nonepileptic neurological features in subjects carrying single nucleotide variant and copynumber variation mutations of STXBP1. Diffuse tremor was observed in two cases reported by Hamdan et al., 17 three cases reported by Mignot et al., 10 and two cases described by Milh et al.
14 Ataxia and dyskinesia were observed in five subjects studied by Deprez et al., 16 and myoclo nic jerks were reported in four cases described by Milh et al. 14 Stereotypic hand movements were noticed in the three sub jects reported by Mignot et al. 10 and in two subjects reported by Milh et al. 14 Moreover, a number of subjects harboring a missense mutation in STXBP1 and exhibiting nonepileptic movement symptoms have been described (Supplementary  Table S3 , online). 8, 14, 26, 27 In the context of neurophysiological consequences of STXBP1 variation, many of these neurological manifestations may be the result of impaired release of excit atory and inhibitory neurotransmitters that normally regulate the function of the indirect pathway of the motor loop. This circuit connects the basal ganglia, thalamus, and motor cortex, and its disruption may lead to involuntary movement activi ty. 28 These associated neurological findings suggest that early disruption in brain development and maturation of the central nervous system caused by STXBP1 mutations and deletions may result in a broad constellation of clinical neurological findings, including different epilepsies, isolated nonsyndromic ID, movement disorders, and ASDs with the ensuing pheno type depending on the additive effects of genetic modifiers and environmental factors for each affected individual. 25 Deletions in five subjects in our cohort (P1-P3, P6, and P9; Table 1 ) involve the entire SPTAN1 coding sequence. Recent reports have shown that alterations in SPTAN1 may present with IS, severe central hypomyelination, and ID.
29 SPTAN1 encodes α2 spectrin, the major αspectrin expressed in nonerythroid cells and an essential protein involved in proper myelination in zebrafish. 30 Two subjects with SPTAN1 mutations and one with a complex rearrangement of 9q34.11 involving both STXBP1 and SPTAN1 presented with earlyonset IS, severe hypomy elination, spastic quadriplegia, visual impairment, and global DD. 29 Moreover, a separate group has reported another subject with deletion of both STXBP1 and SPTAN1 who presented with IS, generalized tremor, stereotypic movements, global cerebral atrophy, and ID. 14 Three patients reported here have 9q34.11 deletions encom passing both STXBP1 and SPTAN1 (P1-P3; Figure 1 , Table 1) , and two patients have deletions of SPTAN1 without deletion of STXBP1 coding sequence (P6 and P9; Figure 1 , Table 1 ). Nonetheless, only two patients (P2 and P3) in our cohort manifested epilepsy, and both of these patients' deletions also harbored STXBP1 coding sequence. These results suggest that SPTAN1 haploinsufficiency alone may not necessarily lead to an epileptic phenotype. Moreover, although hypomyelination and atrophy of the brainstem and cerebellum were reported before in patients with SPTAN1 mutations, only P9 from this study had documented hypomyelination on neuroimaging. These findings point towards a less deleterious effect associ ated with lossoffunction mutations as compared to a poten tial dominant negative (antemorphic) or gainoffunction (neomorphic) effect caused by inframe SPTAN1 mutations. It has been postulated that inframe SPTAN1 mutations may exert a dominant negative effect by aggregation of mutant αII/ wildtype βII and mutant αII/wildtype βIII spectrin het erodimers. 29 Such defective heterodimers may cause instability of membrane proteins, including ion channels, localized to the axon initial segment, while simultaneously altering intracellu lar vesicular transport. 31 Therefore, distorted cytoskeletal scaf folds caused by the effect of inframe SPTAN1 mutations may result in more detrimental neurological phenotypes. 29 These findings could explain the absence of epilepsy in some patients with SPTAN1 deletions described in this study and the find ing of hypomyelination in only one of the subjects reported herein. When hypomyelination was previously reported in subjects with SPTAN1 deletion, a normal myelination pattern was observed over time. 29 Genomic deletions involving ENG have been observed in individuals with hereditary hemorrhagic telangiectasia type 1 (HHT1), 32, 33 supporting the hypothesis that ENG haploinsuf ficiency is the molecular etiology of HHT1. ENG disruption leads to abnormal vascular development ranging from dilated microvessels to large arteriovenous malformations with poten tially lethal complications. HHT1associated phenotypes can be quite variable, but the disorder often presents with earlyon set recurrent spontaneous epistaxis. Four patients (P1-P3 and P10; Table 1 ) in this study have deletions involving the ENG gene. In patient 2, a pulmonary arteriovenous malformation was discovered incidentally upon evaluation for respiratory distress and low oxygen saturation levels. As the clinical phe notype associated with HHT1 tends to develop during child hood and adolescence and paucity of clinical features such as epistaxis, telangiectasias, or symptoms of solid organ arterio venous malformation are not uncommon in affected children, 34 it is not surprising to find that the other three patients harbor ing ENG deletions in our cohort do not manifest symptoms. Clinical findings in P2 illustrate the necessity of highresolution molecular analysis to precisely identify gene content in patients with 9q34.11 deletions, which can be used for accurate genetic counseling and appropriate monitoring for early detection of systemic complications when ENG is deleted.
In four members of our cohort (P1 and P6-P8; Table 1 ) the TOR1A gene is deleted. TOR1A encodes the protein torsin1A (torsin A). A 3 bp deletion, c.907_909delGAG, in this gene has been found in all patients with earlyonset primary torsion dys tonia type 1 in whom a definitively causative molecular lesion has been identified. 35 The disease is more prevalent in patients of Ashkenazi Jewish ancestry because of a founder effect. 36 Torsion dystonia type 1 is an autosomal dominant condition with age dependent penetrance; asymptomatic subjects known to harbor the TOR1A diseasecausing mutation have a 30-40% chance of developing clinical manifestations. Evidence from mouse models suggests TOR1A c.907_909delGAG is a lossoffunction allele, but a dominant negative (antemorphic) effect cannot be exclud ed. 37 Decreased penetrance may be because of the presence of an in trans genetic modifier within the TOR1A gene itself. 38 Thus, the fact that only one (P8) of our four patients with TOR1A dele tions exhibits dystonia is not unexpected. Aside from the mani festation of dystonia and tremor, patients with torsion dystonia type 1 display no other neurological or cognitive abnormalities. Therefore, the presence of moderate ID and dysmorphic fea tures in the four subjects of our cohort is probably because of the influence of deleted neighboring genes.
In addition to the four genes detailed above, coding sequence of 94 other RefSeq genes was contained within the deletion of at least one patient in our cohort (Supplementary Table S2 , online). None of the additional genes can be found in a previ ously published list of haploinsufficient genes. 39 Nine of these genes are associated with human phenotypes: SLC27A4 (MIM 608649), AK1 (MIM 612631), LAMC3 (MIM 614115), DOLK (MIM 610768), LRRC8A (MIM 613506), LRSAM1 (MIM 614436), GLE1 (MIMs 253310, 611890), ASS1 (MIM 215700), and MIR2861 (MIM 613418). However, among all of the phe notypes listed, only the underlying molecular mechanism for CharcotMarieTooth type 2P, caused by defects in LRSAM1, may be possibly related to haploinsufficiency. 40 Because the ear liest onset of CMT type 2P is during the third decade of life, haploinsufficiency of LRSAM1 is unlikely to contribute to the current phenotypes of P3 and P10.
Overall, seven of the 10 patients had mildly dysmorphic fea tures; however, these features were heterogeneous, and no char acteristic facial "gestalt" is shared among them. A longitudinal clinical study enrolling a larger number of subjects with these deletions will be required to identify potentially consistent dys morphic features and to delineate the extent to which dosage sensitive gene content could play a role.
In conclusion, interstitial nonrecurrent deletions in the generich 9q34.11 region in our patients vary in size from 67 kb to 2.8 Mb and have different breakpoints. The microdele tions often span multiple dosagesensitive genes, suggesting that the resultant overall phenotype could arise from combina tions of cisgenetic effects. Physical proximity of at least four dosagesensitive genes (STXBP1, SPTAN1, ENG, and TOR1A) within the 9q34.11 region adds further complexity to the observed phenotype and clinical course of these subjects. We propose that highresolution chromosomal microarray analy sis, including coverage for 9q34.11 microdeletions, should be considered in infants and children with earlyonset epilepsy or severe progressive encephalopathy associated with DD or ID; STXBP1 haploinsufficiency may be an underascertained cause of such phenotypes. Patients with 9q34.11 deletions involving the ENG gene can present with arteriovenous malformations in lungs, spinal cord, and brain; those with deletions involving the TOR1A gene can present with dystonia. The identification and extensive genomic and clinical studies of additional patients is necessary to elucidate the role of SPTAN1 haploinsufficiency as well as the clinical consequences of other dosagesensitive genes and cisgenetic effects in the 9q34.11 region.
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